GH Research (GHRS)
NASDAQ:GHRS
GHRS Stock Chart & Stats
$14.72
-$0.22(-2.41%)
At close: 4:00 PM EST
$14.72
-$0.22(-2.41%)
Day’s Range― - ―
52-Week Range$7.98 - $19.51
Previous CloseN/A
Volume14.35K
Average Volume (3M)209.96K
Market Cap
$913.07M
Enterprise Value$667.33M
Total Cash (Recent Filing)$280.71M
Total Debt (Recent Filing)$512.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 07, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding62,029,396
10 Day Avg. Volume189,216
30 Day Avg. Volume209,960
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.58K
Enterprise Value/Ebitda-13.23
Forecast
1Y Price Target
$41.29Price Target Upside180.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.44
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Dosing ProfilePhase 2b and extension data showed rapid, durable remission with short clinic visits and a favorable safety profile, supporting commercial appeal for an infrequently dosed inhaled therapy.
Device Comparability And Safety BridgingA planned clinical pharmacology bridging study is intended to demonstrate comparability of the proprietary aerosol delivery device to prior data and to address species‑specific toxicology concerns for global submissions.
Regulatory ClearanceFDA lifted the clinical hold on the investigational new drug application for GH001, clearing the path to initiate a pivotal global Phase 3 program for treatment‑resistant depression.
Bears Say
Device Gating And International Regulatory RiskA mandatory bridging study with the proprietary device must be completed before the pivotal program can start, making device comparability a gating factor and leaving non‑US regulatory acceptance uncertain.
Financing And Execution RiskThe development plan assumes future financing, exposing the program to execution risk and potential shareholder dilution if additional capital is required.
Regulatory And Trial‑design UncertaintyAdvancement of GH001 depends on obtaining formal FDA agreement on the Phase 3 trial design, and lack of definitive alignment creates regulatory uncertainty that could delay the pivotal program.
GH Research News
GHRS FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was $7.98 and its highest was $19.51 in the past 12 months.
What is GH Research’s market cap?
GH Research’s market cap is $913.07M.
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is May 07, 2026 which is in 35 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Mar 05, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.264 by $0.034.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -0.29.
How many shares outstanding does GH Research have?
GH Research has 62,029,396 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.264. Following the earnings report the stock price went down -5.128%.
Which hedge fund is a major shareholder of GH Research?
Currently, no hedge funds are holding shares in GHRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.29 (180.50% Upside)
$41.29 (180.50% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 18.9%
Last 30 Days ▲ 18.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.81%
12-Months-Change
Fundamentals
Return on Equity
-16.30%
Trailing 12-Months
Asset Growth
53.09%
Trailing 12-Months
Company Description
GH Research
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GHRS Stock 12 Month Forecast
Average Price Target
$41.29
▲(180.50% Upside)
Technical Analysis
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
4.22% Mutual Funds
61.41% Other Institutional Investors
33.41% Public Companies and Individual Investors